Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

This is an Open, Single-arm, Clinical Study to Evaluate the Efficacy and Safety of Anti-CD7/CD5 CAR-T Cells in the Treatment of Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL), ETP-ALL, and Lymphoblastic Lymphoma (TLBL).

NCT06420076 is registered in ClinicalTrials.gov with Essen Biotech as lead sponsor.

NCT NCT06420076
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06420076 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
This is an Open, Single-arm, Clinical Study to Evaluate the Efficacy and Safety of Anti-CD7/CD5 CAR-T Cells in the Treatment of Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL), ETP-ALL, and Lymphoblastic Lymphoma (TLBL).
Lead sponsor
Essen Biotech
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 10, 2024
Completion date
December 28, 2026
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

t cell childhood all, t cell leukemia, t cell lymphoma, t cell prolymphocytic leukemia, t-cell acute lymphoblastic leukemia, t-cell lymphoma of cns